Show simple item record

dc.contributor.authorRojas, Manuel
dc.contributor.authorRodríguez, Yhojan
dc.contributor.authorMonsalve, Diana M.
dc.contributor.authorAcosta Ampudia, Yeny
dc.contributor.authorCamacho, Bernardo
dc.contributor.authorGallo, Juan Esteban
dc.contributor.authorRojas Villarraga, Adriana
dc.contributor.authorRamírez Santana, Carolina
dc.contributor.authorDíaz Coronado, Juan C.
dc.contributor.authorManrique, Rubén
dc.contributor.authorMantilla, Rubén D.
dc.contributor.authorShonenfeld, Yehuda
dc.contributor.authorAnaya, Juan Manuel
dc.date.accessioned2021-08-20T15:14:55Z
dc.publisherResearch Center for Autoimmune Diseasesspa
dc.description.abstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019(COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, and vaccines are under study.Meanwhile the current pandemic has called attention over old therapeutic tools to treat infectious diseases.Convalescent plasma (CP) constitutes thefirst option in the current situation, since it has been successfully usedin other coronaviruses outbreaks. Herein, we discuss the possible mechanisms of action of CP and their re-percussion in COVID-19 pathogenesis, including direct neutralization of the virus, control of an overactiveimmune system (i.e., cytokine storm, Th1/Th17 ratio, complement activation) and immunomodulation of ahypercoagulable state. All these benefits of CP are expected to be better achieved if used in non-criticallyhospitalized patients, in the hope of reducing morbidity and mortality.eng
dc.date.issued2020-07
dc.sourcehttps://www.sciencedirect.com/science/article/pii/S1568997220301166spa
dc.format.extent9 p.spa
dc.titleConvalescent plasma in Covid-19: Possible mechanisms of actioneng
dc.format.mimetypeapplication/pdfspa
dc.typeArtículo de revistaspa
dc.date.available2021-08-20T15:14:55Z
dc.identifier.urihttps://repositorio.fucsalud.edu.co/handle/001/1719
dc.language.isoengspa
dc.relation.ispartofAutoimmunity Reviews e-ISSN:1873-0183 Vol.19 Núm.7 (2020)
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)spa
dc.rights.urihttps://creativecommons.org/licenses/by-nd/4.0/spa
dc.subject.proposalCoronavirusspa
dc.subject.proposalCOVID-19spa
dc.subject.proposalSARS-COV-2spa
dc.subject.proposalConvalecenciaspa
dc.subject.proposalCitocinasspa
dc.subject.proposalInmunoglobinas intravenosasspa
dc.subject.proposalAnticuerpos neutralizantesspa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.driverinfo:eu-repo/semantics/articlespa
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dc.subject.decsAnticuerpos
dc.publisher.placeHolandaspa
dc.relation.citationendpage102554spa
dc.relation.citationissue7spa
dc.relation.citationstartpage102554spa
dc.relation.citationvolume19spa
dc.relation.ispartofjournalAutoimmunity Reviewsspa
dc.type.contentTextspa
dc.type.coarversionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2spa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/openAccess
Except where otherwise noted, this item's license is described as info:eu-repo/semantics/openAccess